Watson Progresses on Rapaflo - Analyst Blog
May 19 2011 - 7:30AM
Zacks
Watson Pharmaceuticals Inc. (WPI) recently
reported positive data from a mid-stage trial on Rapaflo, for the
reduction of symptoms of moderate to severe chronic
prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Chronic pelvic pain syndrome is characterized by persistent
discomfort in the lower pelvic area, thereby affecting the quality
of life of the sufferer. Symptoms of CPPS include painful and
frequent urination and difficult or painful ejaculation.
The trial results demonstrated that the 4 mg and 8 mg doses of
Rapaflo significantly decreased the symptoms of CPPS and improved
the quality of life. Moreover, patients treated with the same
dosage strengths of Rapaflo showed significantly better results
compared to patients treated with placebo. Additionally, in a
global response assessment, 56% of patients treated with Rapaflo 4
mg reported moderate or marked improvement in the symptoms of CPPS
compared to 29% of patients on placebo.
We note that Rapaflo is already on the market for the treatment
of signs and symptoms of benign prostatic hyperplasia (BPH).
Rapaflo was originally developed by Japanese company Kissei
Pharmaceutical Co., Ltd., which has a licensing deal with Watson
Pharma for the marketing of the drug in the US, Canada and
Mexico.
Watson Pharma was recently in the news for the launch of
authorized generics of Cephalon Inc.’s (CEPH)
Amrix (15 mg and 30 mg) and Johnson &
Johnson’s (JNJ) Concerta. While Cephalon markets Amrix to
help control muscle spasm associated with acute, painful
musculoskeletal conditions, Concerta is used for the treatment of
attention deficit hyperactivity disorder (ADHD) in children aged 6
to 17 and adults aged 18 to 65 years.
Neutral on Watson Pharma
We currently have a Neutral recommendation on Watson Pharma. We
believe that the company’s cost saving initiative and new product
launches, both branded and generic, will help drive long-term
growth.
CEPHALON INC (CEPH): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
WATSON PHARMA (WPI): Free Stock Analysis Report
Zacks Investment Research
Cephalon (NASDAQ:CEPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cephalon (NASDAQ:CEPH)
Historical Stock Chart
From Jul 2023 to Jul 2024